Neukio Biotherapeutics is pioneering the development of next-generation allogenic cell therapies, specifically through the innovative iPSC-CAR-NK (induced pluripotent stem cell-chimeric antigen receptor-natural killer) axis. This approach leverages the unique properties of NK cells, which can be universally applied and readily available for allogeneic use. The company emphasizes the scalability of these therapies, as NK cells can be manufactured in large quantities through iPSC differentiation and banking. Engineered NK cells hold significant promise for targeting and eradicating solid tumors, making them a focal point of Neukio's research and development efforts.

The company operates a state-of-the-art research and manufacturing facility that spans 60,000 square feet, equipped with discovery labs, process sciences, GMP (Good Manufacturing Practice) clean rooms, and quality control laboratories. Neukio employs a high-efficiency, high-yield modular product development technology platform, which enhances their ability to innovate and streamline the process of developing new cell therapies. This comprehensive infrastructure supports their commitment to advancing cell therapy solutions that are patient-centered and quality-oriented, ultimately aiming to transform the future of cancer treatment.

China

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.


Neukio Biotherapeutics

Company Details